Redeye leaves a comment following OncoZenge’s announcement of the completed readout from its UCLA-led patient engagement study for BupiZenge. We are encouraged to see that the study not only confirms the significant unmet need in oral mucositis pain, but that its insights have already been integrated into the phase III protocol and CTA, representing a concrete de-risking step ahead of the pivotal trial.
LÄS MER
